Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469300 · ClinicalTrials.gov registry record · Phase 2
Iontophoretic Application of Acyclovir Gel to Treat Cold Sores
A Phase 2 study, sponsored by Transport Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 810
- Enrollment target
NCT00469300: Completed Phase 2 study, sponsored by Transport Pharmaceuticals.
NCT00469300 is a Phase 2 study that has completed, run by Transport Pharmaceuticals. The registered enrollment target is 810 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (509% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00469300, a Phase 2 study, has completed, sponsored by Transport Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 810 participants
- Enrollment target
Study Summary
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating. Iontophoresis uses electric current to enhance delivery of drugs through the skin. This trial is testing a new iontophoretic device with a new acyclovir gel to treat cold sores.
Interventions
- DRUG Iontophoretic delivery of acyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
What the finished NCT00469300 record still lists
NCT00469300 is an interventional study that assigns participants to a tested intervention. The registered 810 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (509% higher).
The record links to 0 conditions, and to 1 intervention - of which Iontophoretic delivery of acyclovir is the first listed.
NCT00469300 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00469300 about?
NCT00469300 is a clinical study titled "Iontophoretic Application of Acyclovir Gel to Treat Cold Sores". Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating. Iontophoresis uses electric current to enhance delivery of drugs through the ski...
What is the current status of trial NCT00469300?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 810 participants. The study started on 2007-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00469300?
The interventions under investigation include: Iontophoretic delivery of acyclovir (DRUG).
Who is sponsoring clinical trial NCT00469300?
This trial is sponsored by Transport Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00469300's enrollment target sits among peer trials
810 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia